Inactive Instrument

Hutchison China MediTech Limited Stock price London S.E.

Equities

KYG4672N1198

Pharmaceuticals

Sales 2024 * 686M 0 Sales 2025 * 842M 0 Capitalization 2.89B 0
Net income 2024 * -103M - Net income 2025 * -6M - EV / Sales 2024 * 3.89 x
Net cash position 2024 * 217M 0 Net cash position 2025 * 184M 0 EV / Sales 2025 * 3.21 x
P/E ratio 2024 *
-25.2 x
P/E ratio 2025 *
644 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.37%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Hutchison China MediTech Limited

Managers TitleAgeSince
Chief Executive Officer 66 04-12-31
Director of Finance/CFO 57 08-06-30
Chief Tech/Sci/R&D Officer 59 21-12-31
Members of the board TitleAgeSince
Chairman 72 99-12-31
Director/Board Member 73 17-02-28
Director/Board Member 70 16-07-31
More insiders
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
More about the company
  1. Stock
  2. Equities
  3. Stock HUTCHMED (China) Limited
  4. Stock Hutchison China MediTech Limited - London S.E.